Thus, these findings suggest that the tissue origin and resulting epigenetic landscape of a cell is a crucial determinant in mediating the response and mechanism of action of BET protein inhibitors, an important consideration for the future development of therapies targeting epigenetic proteins in cancer cells. The gene discussed is DNER; the disease is cancer.